3820 related articles for article (PubMed ID: 25676540)
1. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
2. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
[TBL] [Abstract][Full Text] [Related]
3. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT.
Gunn H; Andrade J; Paul L; Miller L; Creanor S; Stevens K; Green C; Ewings P; Barton A; Berrow M; Vickery J; Marshall B; Zajicek J; Freeman J
Health Technol Assess; 2019 Jun; 23(27):1-166. PubMed ID: 31217069
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
6. Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT.
Witham MD; Band M; Chong H; Donnan PT; Hampson G; Hu MK; Littleford R; Lamb E; Kalra PA; Kennedy G; McNamee P; Plews D; Rauchhaus P; Soiza RL; Sumukadas D; Warwick G; Avenell A
Health Technol Assess; 2020 Jun; 24(27):1-90. PubMed ID: 32568065
[TBL] [Abstract][Full Text] [Related]
7. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
8. Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT.
Palmer R; Dimairo M; Latimer N; Cross E; Brady M; Enderby P; Bowen A; Julious S; Harrison M; Alshreef A; Bradley E; Bhadhuri A; Chater T; Hughes H; Witts H; Herbert E; Cooper C
Health Technol Assess; 2020 Apr; 24(19):1-176. PubMed ID: 32369007
[TBL] [Abstract][Full Text] [Related]
9. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
10. An extended stroke rehabilitation service for people who have had a stroke: the EXTRAS RCT.
Shaw L; Bhattarai N; Cant R; Drummond A; Ford GA; Forster A; Francis R; Hills K; Howel D; Laverty AM; McKevitt C; McMeekin P; Price C; Stamp E; Stevens E; Vale L; Rodgers H
Health Technol Assess; 2020 May; 24(24):1-202. PubMed ID: 32468989
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
[TBL] [Abstract][Full Text] [Related]
12. Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years.
Robertson W; Fleming J; Kamal A; Hamborg T; Khan KA; Griffiths F; Stewart-Brown S; Stallard N; Petrou S; Simkiss D; Harrison E; Kim SW; Thorogood M
Health Technol Assess; 2017 Jan; 21(1):1-180. PubMed ID: 28059054
[TBL] [Abstract][Full Text] [Related]
13. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
14. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
Shaw L; Rodgers H; Price C; van Wijck F; Shackley P; Steen N; Barnes M; Ford G; Graham L;
Health Technol Assess; 2010 May; 14(26):1-113, iii-iv. PubMed ID: 20515600
[TBL] [Abstract][Full Text] [Related]
15. Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT.
Lamb SE; Mistry D; Alleyne S; Atherton N; Brown D; Copsey B; Dosanjh S; Finnegan S; Fordham B; Griffiths F; Hennings S; Khan I; Khan K; Lall R; Lyle S; Nichols V; Petrou S; Zeh P; Sheehan B
Health Technol Assess; 2018 May; 22(28):1-202. PubMed ID: 29848412
[TBL] [Abstract][Full Text] [Related]
16. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
17. Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.
Lincoln NB; Bradshaw LE; Constantinescu CS; Day F; Drummond AE; Fitzsimmons D; Harris S; Montgomery AA; das Nair R
Health Technol Assess; 2020 Jan; 24(4):1-182. PubMed ID: 31934845
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
19. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
Banerjee S; Farina N; Henderson C; High J; Stirling S; Shepstone L; Fountain J; Ballard C; Bentham P; Burns A; Fox C; Francis P; Howard R; Knapp M; Leroi I; Livingston G; Nilforooshan R; Nurock S; O'Brien J; Price A; Thomas AJ; Swart AM; Telling T; Tabet N
Health Technol Assess; 2023 Oct; 27(23):1-108. PubMed ID: 37929672
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
